A D Marshall1, J Grebely2, G J Dore3, C Treloar4. 1. The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia; Centre for Social Research in Health, UNSW Sydney, Sydney, NSW 2052, Australia. Electronic address: amarshall@kirby.unsw.edu.au. 2. The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia. Electronic address: jgrebely@kirby.unsw.edu.au. 3. The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia. Electronic address: gdore@kirby.unsw.edu.au. 4. Centre for Social Research in Health, UNSW Sydney, Sydney, NSW 2052, Australia. Electronic address: c.treloar@unsw.edu.au.
Abstract
BACKGROUND: Since the advent of interferon-free, direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection, prescriber restrictions have been removed worldwide, permitting HCV management outside of hospital-based clinics. To date, there is limited knowledge of the practitioner experience with DAA treatments, particularly among those new to HCV care. The aim of this qualitative study was to investigate barriers and facilitators for HCV management among general practitioners (GPs) who prescribe opioid agonist therapy (OAT) and drug and alcohol specialists. METHODS: In-depth, semi-structured telephone interviews were conducted between September 2018 and April 2019. Practitioners from across Australia were purposively sampled and questioned on barriers and facilitators to HCV management in their clinic(s). Data were coded and analysed with iterative categorisation and thematical analysis. RESULTS: Thirty practitioners were interviewed. Participants expressed professional fulfillment in managing HCV care and many benefited from specialist mentorship. Most participants expressed frustration with ongoing implementation barriers, notably, a lack of onsite phlebotomy services and liver disease staging equipment. Poor venous access among persons who inject drugs was elucidated as a major barrier to treatment initiation. Some participants did not receive clinic manager support to engage in HCV care. CONCLUSION: To achieve HCV targets set by WHO by 2030, practitioners require additional implementation support. As HCV testing remains a barrier to linkage to care, practitioners should be kept well-informed of diagnostic developments. Findings also underscore the importance of initial specialist mentorship with further evidence needed for practitioners based in rural regions.
BACKGROUND: Since the advent of interferon-free, direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection, prescriber restrictions have been removed worldwide, permitting HCV management outside of hospital-based clinics. To date, there is limited knowledge of the practitioner experience with DAA treatments, particularly among those new to HCV care. The aim of this qualitative study was to investigate barriers and facilitators for HCV management among general practitioners (GPs) who prescribe opioid agonist therapy (OAT) and drug and alcohol specialists. METHODS: In-depth, semi-structured telephone interviews were conducted between September 2018 and April 2019. Practitioners from across Australia were purposively sampled and questioned on barriers and facilitators to HCV management in their clinic(s). Data were coded and analysed with iterative categorisation and thematical analysis. RESULTS: Thirty practitioners were interviewed. Participants expressed professional fulfillment in managing HCV care and many benefited from specialist mentorship. Most participants expressed frustration with ongoing implementation barriers, notably, a lack of onsite phlebotomy services and liver disease staging equipment. Poor venous access among persons who inject drugs was elucidated as a major barrier to treatment initiation. Some participants did not receive clinic manager support to engage in HCV care. CONCLUSION: To achieve HCV targets set by WHO by 2030, practitioners require additional implementation support. As HCV testing remains a barrier to linkage to care, practitioners should be kept well-informed of diagnostic developments. Findings also underscore the importance of initial specialist mentorship with further evidence needed for practitioners based in rural regions.
Authors: Donna M Evon; Christopher B Hurt; Delesha M Carpenter; Sarah K Rhea; Caitlin M Hennessy; William A Zule Journal: Rural Ment Health Date: 2022-02-03
Authors: Sabrina A Assoumou; Carlos R Sian; Christina M Gebel; Benjamin P Linas; Jeffrey H Samet; Judith A Bernstein Journal: Drug Alcohol Depend Date: 2021-01-11 Impact factor: 4.492
Authors: Sofia R Bartlett; Stanley Wong; Amanda Yu; Margo Pearce; Julia MacIsaac; Susan Nouch; Prince Adu; James Wilton; Hasina Samji; Emilia Clementi; Hector Velasquez; Dahn Jeong; Mawuena Binka; Maria Alvarez; Jason Wong; Jane Buxton; Mel Krajden; Naveed Z Janjua Journal: Clin Infect Dis Date: 2022-03-01 Impact factor: 20.999
Authors: David Whiteley; Elizabeth Speakman; Lawrie Elliott; Katherine Davidson; Emma Hamilton; Helen Jarvis; Michael Quinn; Paul Flowers Journal: J Viral Hepat Date: 2020-12-07 Impact factor: 3.728
Authors: Jasmine Yee; Joanne M Carson; Behzad Hajarizadeh; Joshua Hanson; James O'Beirne; David Iser; Phillip Read; Anne Balcomb; Joseph S Doyle; Jane Davies; Marianne Martinello; Philiipa Marks; Gregory J Dore; Gail V Matthews Journal: Hepatol Commun Date: 2021-11-02